Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes

Cardiovascular Research

Volumn 63, Issue 3, 2004, Pages 450-457

  Fiedler, Beate ^a   Wollert, Kai C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Calcium (cellular); Hypertrophy; Protein phosphatases; Signal transduction

Indexed keywords

BILIVERDIN; CALCINEURIN; CALCINEURIN B HOMOLOGY PROTEIN; CALCINEURIN BINDING PROTEIN 1; CALCINEURIN INHIBITOR; CALCINEURIN INHIBITORY PROTEIN; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC GMP; CYCLOSPORIN A; GLYCOGEN SYNTHASE KINASE 3; HEME OXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN KINASE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

DEPHOSPHORYLATION; DISEASE COURSE; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEART WORK; HUMAN; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CALCINEURIN; CALCIUM; CARDIOMYOPATHY, DILATED; DNA-BINDING PROTEINS; HUMANS; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 3242770551     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.04.002     Document Type: Review

References (79)

1. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 100:1999;999-1008
2. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:2003;45-79
3. Bartunek J., Weinberg E.O., Tajima M., et al. Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation. 101:2000;423-429
4. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 105:2002;85-92
5. Dorn G.W. II, Robbins J., Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 92:2003;1171-1175
6. Hunter J.J., Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341:1999;1276-1283
7. Molkentin J.D., Dorn I.G. II Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:2001;391-426
8. 2+, calcineurin, and NF-AT. Cell. 96:1999;611-614
9. Alzuherri H., Chang K.C. Calcineurin activates NF-kappaB in skeletal muscle C2C12 cells. Cell. Signal. 15:2003;471-478
10. Lilienbaum A., Israel A. From calcium to NF-kappa B signaling pathways in neurons. Mol. Cell. Biol. 23:2003;2680-2698
11. 2+-dependent gene expression mediated by MEF2 transcription factors. J. Biol. Chem. 275:2000;197-209
12. Passier R., Zeng H., Frey N., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:2000;1395-1406
13. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 284:1999;339-343
14. Bueno O.F., vanRooij E., Molkentin J.D., Doevendans P.A., DeWindt L.J. Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc. Res. 53:2002;806-821
15. Yamamoto K., Ohki R., Lee R.T., Ikeda U., Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 104:2001;1670-1675
16. Asakawa M., Takano H., Nagai T., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:2002;1240-1246
17. Bueno O.F., DeWindt L.J., Lim H.W., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ. Res. 88:2001;88-96
18. Calderone A., Thaik C.M., Takahashi N., Chang D.L., Colucci W.S. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101:1998;812-818
19. Wollert K.C., Fiedler B., Gambaryan S., et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension. 39:2002;87-92
20. Fiedler B., Lohmann S.M., Smolenski A., et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11363-11368
21. Wollert K.C., Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail. Rev. 7:2002;317-325
22. Holtwick R., van Eickels M., Skryabin B.V., et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest. 111:2003;1399-1407
23. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 93:2003;700-709
24. Heineke J., Kempf T., Kraft T., et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation. 107:2003;1424-1432
25. Crabtree G.R. Calcium, calcineurin, and the control of transcription. J. Biol. Chem. 276:2001;2313-2316
26. Kato T., Sano M., Miyoshi S., et al. Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. Circ. Res. 87:2000;937-945
27. Taigen T., De Windt L.J., Lim H.W., Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1196-1201
28. Wegener J.W., Nawrath H., Wolfsgruber W., et al. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ. Res. 90:2002;18-20
29. 2+ channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice. Cardiovasc. Res. 60:2003;268-277
30. 2+-dependent transgenic model of cardiac hypertrophy: a role for protein kinase Calpha. Circulation. 103:2001;140-147
31. Semsarian C., Ahmad I., Giewat M., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109:2002;1013-1020
32. 2+ current characteristics in endo- and epicardial myocytes from rat left ventricle with pressure-induced hypertrophy. Pflugers Arch. 443:2002;399-404
33. Lim H.W., Molkentin J.D. Calcineurin and human heart failure. Nat. Med. 5:1999;246-247
34. Haq S., Choukroun G., Lim H., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103:2001;670-677
35. Maines M.D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2:1988;2557-2568
36. Tongers J., Fiedler B., Kempf T., et al. Suppression of cardiac myocyte hypertrophy by heme oxygenase-1: role of MAP-kinase and calcineurin-NFAT inhibition. Cardiovasc. Res. 2004;. this issue
37. McCaffrey P.G., Luo C., Kerppola T.K., et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science. 262:1993;750-754
38. Shaw K.T., Ho A.M., Raghavan A., et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11205-11209
39. Shaw J.P., Utz P.J., Durand D.B., et al. Identification of a putative regulator of early T cell activation genes. Science. 241:1988;202-205
40. Sun L., Youn H.D., Loh C., et al. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity. 8:1998;703-711
41. Lai M.M., Burnett P.E., Wolosker H., Blackshaw S., Snyder S.H. Cain, a novel physiologic protein inhibitor of calcineurin. J. Biol. Chem. 273:1998;18325-18331
42. Coghlan V.M., Perrino B.A., Howard M., et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science. 267:1995;108-111
43. Lin X., Sikkink R.A., Rusnak F., Barber D.L. Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J. Biol. Chem. 274:1999;36125-36131
44. Carr D.W., Stofko-Hahn R.E., Fraser I.D., Cone R.D., Scott J.D. Localization of the cAMP-dependent protein kinase to the postsynaptic densities by A-kinase anchoring proteins characterization of AKAP 79. J. Biol. Chem. 267:1992;16816-16823
45. DeWindt L.J., Lim H.W., Bueno O.F., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3322-3327
46. Rothermel B., Vega R.B., Yang J., et al. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J. Biol. Chem. 275:2000;8719-8725
47. Fuentes J.J., Genesca L., Kingsbury T.J., et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 9:2000;1681-1690
48. Strippoli P., Lenzi L., Petrini M., Carinci P., Zannotti M. A new gene family including DSCR1 (Down Syndrome Candidate Region 1) and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2). Genomics. 64:2000;252-263
49. Yang J., Rothermel B., Vega R.B., et al. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ. Res. 87:2000;E61-68
50. Rothermel B.A., McKinsey T.A., Vega R.B., et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;:3328-3333
51. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228
52. vanRooij E., Doevendans P.A., Crijns H.J., et al. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ. Res. 94:2004;e18-e26
53. Wilkins B.J., Dai Y.S., Bueno O.F., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 2004;94
54. Vega R.B., Rothermel B.A., Weinheimer C.J., et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:2003;669-674
55. Aramburu J., Yaffe M.B., Lopez-Rodriguez C., et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 285:1999;2129-2133
56. Pu W.T., Ma Q., Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ. Res. 92:2003;725-731
57. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev., Mol. Cell Biol. 2:2001;769-776
58. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:1995;785-789
59. Delcommenne M., Tan C., Gray V., et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11211-11216
60. Dajani R., Fraser E., Roe S.M., et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105:2001;721-732
61. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 275:1997;1930-1934
62. Hardt S.E., Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90:2002;1055-1063
63. Haq S., Choukroun G., Kang Z.B., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151:2000;117-130
64. Antos C.L., McKinsey T.A., Frey N., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99:2002;907-912
65. Hilioti Z., Gallagher D.A., Low-Nam S.T., et al. GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. Genes Dev. 18:2004;35-47
66. Vega R.B., Yang J., Rothermel B.A., Bassel-Duby R., Williams R.S. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J. Biol. Chem. 277:2002;30401-30407
67. Zhu J., Shibasaki F., Price R., et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell. 93:1998;851-861
68. Molkentin J.D. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 63:2004;467-475. this issue
69. Liang Q., Bueno O.F., Wilkins B.J., et al. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22:2003;5079-5089
70. Braz J.C., Bueno O.F., Liang Q., et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 111:2003;1475-1486
71. Gomezdel Arco P., Martinez-Martinez S., Maldonado J.L., Ortega-Perez I., Redondo J.M. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J. Biol. Chem. 275:2000;13872-13878
72. Porter C.M., Havens M.A., Clipstone N.A. Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization. J. Biol. Chem. 275:2000;3543-3551
73. Yang T.T., Xiong Q., Enslen H., Davis R.J., Chow C.W. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol. Cell. Biol. 22:2002;3892-3904
74. Chow C.W., Rincon M., Cavanagh J., Dickens M., Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science. 278:1997;1638-1641
75. Kempf T., Wollert K.C. Nitric oxide and the enigma of cardiac hypertrophy. BioEssays. 2004;. [in press]
76. Brancaccio M., Fratta L., Notte A., et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9:2003;68-75
77. Wilkins B.J., Dai Y.S., Bueno O.F., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94:2004;110-118
78. McMullen J.R., Shioi T., Zhang L., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:2003;12355-12360
79. Bueno O.F., Lips D.J., Kaiser R.A., et al. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ. Res. 94:2004;91-99